Replies to post #110658 on Biotech Values

[DewDiligence]

If memory serves me, this is the THIRD CP filed by TEVA on Copaxone and the first two were rejected not only as premature but with reasons rejecting many of the arguments TEVA advanced.

That’s right. Teva’s first Copaxone CP was rejected by the FDA because it was filed prematurely and Teva’s second CP (the one referenced in my previous post) was rejected by the FDA on the merits.